Your browser doesn't support javascript.
loading
Enhanced anticancer activity and endocytic mechanisms by polymeric nanocarriers of n-butylidenephthalide in leukemia cells
Huang, X-F; Chang, K-F; Sheu, G-T; Lee, M-S; Hsieh, M-C; Tsai, N-M; Lin, Y-L.
Afiliación
  • Huang, X-F; Chung Shan Medical University. Institute of Medicine. Taiwan. ROC
  • Chang, K-F; Chung Shan Medical University. Institute of Medicine. Taiwan. ROC
  • Sheu, G-T; Chung Shan Medical University. Institute of Medicine. Taiwan. ROC
  • Lee, M-S; Chung Shan Medical University. Department of Medical Laboratory and Biotechnology. Taiwan. ROC
  • Hsieh, M-C; Chung Shan Medical University. Department of Medical Laboratory and Biotechnology. Taiwan. ROC
  • Tsai, N-M; Chung Shan Medical University. Department of Medical Laboratory and Biotechnology. Taiwan. ROC
  • Lin, Y-L; Academia Sinica. Agricultural Biotechnology Research Center. Taiwan. ROC
Clin. transl. oncol. (Print) ; Clin. transl. oncol. (Print);23(6): 1142-1151, jun. 2021. graf
Article en En | IBECS | ID: ibc-221335
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Purpose The purpose of this study was to investigate the antitumor mechanisms of n-butylidenephthalide (BP) and to further examine the delivery efficacy of polycationic liposome containing PEI and polyethylene glycol complex (LPPC)-encapsulated BP in leukemia cells. Method MTS, flow cytometric and TUNEL assays were performed to assess cell viability and apoptosis. BP and BP/LPPC complex delivery efficiency was analyzed by full-wavelength fluorescent scanner and fluorescence microscope. The expressions of cell cycle- and apoptosis-related proteins were conducted by Western blotting. Results The results showed that BP inhibited leukemia cell growth by inducing cell cycle arrest and cell apoptosis. LPPC-encapsulated BP rapidly induced endocytic pathway activation, resulting in the internalization of BP into leukemia cells, causing cell apoptosis within 1 h. Conclusions LPPC encapsulation enhanced the cytotoxic activity of BP and did not influence the effects of BP induction that suggested LPPC-encapsulated BP might be developed as anti-leukemia drugs in future (AU)
Asunto(s)
Palabras clave
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Anhídridos Ftálicos / Portadores de Fármacos / Leucemia Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Anhídridos Ftálicos / Portadores de Fármacos / Leucemia Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article